RÉSUMÉ
BackgroundHealthcare personnel (HCP) are at high risk for respiratory infections through occupational exposure to respiratory viruses.AimWe used data from a prospective influenza vaccine effectiveness study in HCP to quantify the incidence of acute respiratory infections (ARI) and their associated presenteeism and absenteeism.MethodsAt the start and end of each season, HCP at two Israeli hospitals provided serum to screen for antibodies to influenza virus using the haemagglutination inhibition assay. During the season, active monitoring for the development of ARI symptoms was conducted twice a week by RT-PCR testing of nasal swabs for influenza and respiratory syncytial virus (RSV). Workplace presenteeism and absenteeism were documented. We calculated incidences of influenza- and RSV-associated ARI and applied sampling weights to make estimates representative of the source population.ResultsThe median age of 2,505 participating HCP was 41 years, and 70% were female. Incidence was 9.1 per 100 person-seasons (95%â¯CI:â¯5.8-14.2) for RT-PCR-confirmed influenza and 2.5 per 100 person-seasons (95%â¯CI:â¯0.9-7.1) for RSV illness. Each season, 18-23% of unvaccinated and influenza-negative HCP seroconverted. The incidence of seroconversion or RT-PCR-confirmed influenza was 27.5 per 100 person-seasons (95%â¯CI:â¯17.8-42.5). Work during illness occurred in 92% (95%â¯CI:â¯91-93) of ARI episodes, absence from work in 38% (95%â¯CI:â¯36-40).ConclusionInfluenza virus and RSV infections and associated presenteeism and absenteeism were common among HCP. Improving vaccination uptake among HCP, infection control, and encouraging sick HCP to stay home are important strategies to reduce ARI incidence and decrease the risk of in-hospital transmission.
Sujet(s)
Absentéisme , Personnel de santé , Grippe humaine , Présentéisme , Infections à virus respiratoire syncytial , Saisons , Humains , Infections à virus respiratoire syncytial/épidémiologie , Infections à virus respiratoire syncytial/diagnostic , Infections à virus respiratoire syncytial/virologie , Grippe humaine/épidémiologie , Grippe humaine/virologie , Grippe humaine/diagnostic , Grippe humaine/prévention et contrôle , Femelle , Incidence , Mâle , Personnel de santé/statistiques et données numériques , Israël/épidémiologie , Adulte , Présentéisme/statistiques et données numériques , Adulte d'âge moyen , Études prospectives , Infections de l'appareil respiratoire/épidémiologie , Infections de l'appareil respiratoire/virologie , Vaccins antigrippaux/administration et posologie , Vaccins antigrippaux/immunologie , Virus respiratoires syncytiaux/isolement et purification , Virus respiratoire syncytial humain/isolement et purification , Virus respiratoire syncytial humain/génétique , Exposition professionnelle/statistiques et données numériques , Tests d'inhibition de l'hémagglutinationRÉSUMÉ
BackgroundA new respiratory virus surveillance platform, based on nationwide hospital laboratory data, was established in Israel during the COVID-19 pandemic.AimWe aimed to evaluate the performance of this platform with respect to the detection of influenza and respiratory syncytial virus (RSV) from week 36 in 2020 to week 15 in 2023, and how it fits with the World Health Organization (WHO) mosaic surveillance framework.MethodsData of respiratory samples from hospitalised patients sent for laboratory confirmation of influenza virus or RSV from 25 general hospital laboratories nationwide were collected. We analysed the weekly number and percentage of samples positive for influenza virus or RSV vis-à-vis SARS-CoV-2 activity and compared data from the new surveillance platform with existing surveillance platforms. Using data in the new surveillance platform, we analysed early stages of a 2021 out-of-season RSV outbreak and evaluated the capabilities of the new surveillance system with respect to objectives and domains of the WHO mosaic framework.ResultsThe new hospital-laboratory surveillance platform captured the activity of influenza virus and RSV, provided crucial data when outpatient sentinel surveillance was not operational and supported an out-of-season RSV outbreak investigation. The new surveillance platform fulfilled important objectives in all three domains of the mosaic framework and could serve for gathering additional information to fulfil more domain objectives.ConclusionThe new hospital laboratory surveillance platform provided essential data during the COVID-19 pandemic and beyond, fulfilled important domain objectives of the mosaic framework and could be adapted for the surveillance of other viruses.
Sujet(s)
COVID-19 , Grippe humaine , Pandémies , Infections à virus respiratoire syncytial , SARS-CoV-2 , Organisation mondiale de la santé , Humains , COVID-19/épidémiologie , Israël/épidémiologie , Infections à virus respiratoire syncytial/épidémiologie , Infections à virus respiratoire syncytial/diagnostic , Grippe humaine/épidémiologie , Grippe humaine/diagnostic , Surveillance sentinelle , Laboratoires hospitaliers/statistiques et données numériques , Virus respiratoire syncytial humain/isolement et purification , Surveillance de la population/méthodesRÉSUMÉ
We developed and validated the Influenza Severity Scale (ISS), a standardized risk assessment for influenza, to estimate and predict the probability of major clinical events in patients with laboratory-confirmed infection. Data from the Canadian Immunization Research Network's Serious Outcomes Surveillance Network (2011/2012-2018/2019 influenza seasons) enabled the selecting of all laboratory-confirmed influenza patients. A machine learning-based approach then identified variables, generated weighted scores, and evaluated model performance. This study included 12,954 patients with laboratory-confirmed influenza infections. The optimal scale encompassed ten variables: demographic (age and sex), health history (smoking status, chronic pulmonary disease, diabetes mellitus, and influenza vaccination status), clinical presentation (cough, sputum production, and shortness of breath), and function (need for regular support for activities of daily living). As a continuous variable, the scale had an AU-ROC of 0.73 (95% CI, 0.71-0.74). Aggregated scores classified participants into three risk categories: low (ISS < 30; 79.9% sensitivity, 51% specificity), moderate (ISS ≥ 30 but < 50; 54.5% sensitivity, 55.9% specificity), and high (ISS ≥ 50; 51.4% sensitivity, 80.5% specificity). ISS demonstrated a solid ability to identify patients with hospitalized laboratory-confirmed influenza at increased risk for Major Clinical Events, potentially impacting clinical practice and research.
Sujet(s)
Grippe humaine , Indice de gravité de la maladie , Humains , Grippe humaine/diagnostic , Grippe humaine/épidémiologie , Mâle , Canada/épidémiologie , Femelle , Adulte d'âge moyen , Adulte , Sujet âgé , Appréciation des risques/méthodes , Jeune adulte , AdolescentRÉSUMÉ
INTRODUCTION: A hunter with a history of oncology, flu-like symptoms and ring-shaped erythema was treated with doxycycline in an outpatient setting on suspicion of a tick-borne disease. After obtaining a positive Francisella tularensis serology, antibiotic treatment was continued for a total of 21 days, followed by freedom of symptoms and falling CRP, but without prompt serological follow-up. In contrast to the previously described tularemia cases in Switzerland, the article shows less pronounced local finding without palpable lymphadenopathy.
Sujet(s)
Tularémie , Humains , Mâle , Tularémie/diagnostic , Tularémie/traitement médicamenteux , Diagnostic différentiel , Antibactériens/usage thérapeutique , Doxycycline/usage thérapeutique , Érythème/étiologie , Grippe humaine/diagnostic , Grippe humaine/complications , Francisella tularensis/isolement et purification , Adulte d'âge moyen , SuisseRÉSUMÉ
The multiplex molecular diagnostic assays described for severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), influenza A (IAV) and B (IBV) viruses have been mainly based on real-time reaction, which limits their access to many laboratories or diagnostic institutions. To contribute to available strategies and expand access to differential diagnosis, we describe an end-point multiplex RT-PCR targeting SARS-CoV-2, IAV and IBV with simultaneous endogenous control amplification. Initially, we looked for well-established primers sets for SARS-CoV-2, IAV, IBV and RNAse P whose amplicons could be distinguished on agarose gel. The multiplex assay was then standardized by optimizing the reaction mix and cycle conditions. The limit of detection (LoD) was determined using titrated viruses (for SARS-CoV-2 and IAV) and by dilution from a pool of IBV-positive samples. The diagnostic performance of the multiplex was evaluated by testing samples with different RNAse P and viral loads, previously identified as positive or negative for the target viruses. The amplicons of IAV (146 bp), SARS-CoV-2 (113 bp), IBV (103 bp) and RNAse P (65 bp) were adequately distinguished in our multiplex. The LoD for SARS-CoV-2, IAV and IBV was 0.02 TCID50/ml, 0.07 TCID50/ml and 10-3 from a pool of positive samples, respectively. All samples positive for SARS-CoV-2 (n=70, Ct 17.2-36.9), IAV (n=53, Ct 14-34.9) and IBV (n=12, Ct 23.9-31.9) remained positive in our multiplex assay. RNAse P from negative samples (n=40, Ct 25.2-30.2) was also amplified in the multiplex. Overall, our assay is a timely and alternative tool for detecting SARS-CoV-2 and influenza viruses in laboratories with limited access to supplies/equipment.
Sujet(s)
COVID-19 , Virus de la grippe A , Virus influenza B , Réaction de polymérisation en chaine multiplex , Ribonuclease P , SARS-CoV-2 , Humains , Ribonuclease P/génétique , SARS-CoV-2/génétique , SARS-CoV-2/isolement et purification , Virus de la grippe A/isolement et purification , Virus de la grippe A/génétique , Virus influenza B/isolement et purification , Virus influenza B/génétique , COVID-19/diagnostic , COVID-19/virologie , Réaction de polymérisation en chaine multiplex/méthodes , Diagnostic différentiel , Grippe humaine/diagnostic , Grippe humaine/virologie , Sensibilité et spécificité , RT-PCR/méthodes , Limite de détection , ARN viral/génétique , ARN viral/analyseRÉSUMÉ
BACKGROUND: The rapid transmission and high pathogenicity of respiratory viruses significantly impact the health of both children and adults. Extracting and detecting their nucleic acid is crucial for disease prevention and treatment strategies. However, current extraction methods are laborious and time-consuming and show significant variations in nucleic acid content and purity among different kits, affecting detection sensitivity and efficiency. Our aim is to develop a novel method that reduces extraction time, simplifies operational steps, and ensures high-quality acquisition of respiratory viral nucleic acid. METHODS: We extracted respiratory syncytial virus (RSV) nucleic acid using reagents with different components and analyzed cycle threshold (Ct) values via quantitative real-time polymerase chain reaction (qRT-PCR) to optimize and validate the novel lysis and washing solution. The performance of this method was compared against magnetic bead, spin column, and precipitation methods for extracting nucleic acid from various respiratory viruses. The clinical utility of this method was confirmed by comparing it to the standard magnetic bead method for extracting clinical specimens of influenza A virus (IAV). RESULTS: The solution, composed of equal parts glycerin and ethanol (50% each), offers an innovative washing approach that achieved comparable efficacy to conventional methods in a single abbreviated cycle. When combined with our A Plus lysis solution, our novel five-minute nucleic acid extraction (FME) method for respiratory viruses yielded superior RNA concentrations and purity compared to traditional methods. FME, when used with a universal automatic nucleic acid extractor, demonstrated similar efficiency as various conventional methods in analyzing diverse concentrations of respiratory viruses. In detecting respiratory specimens from 525 patients suspected of IAV infection, the FME method showed an equivalent detection rate to the standard magnetic bead method, with a total coincidence rate of 95.43% and a kappa statistic of 0.901 (P < 0.001). CONCLUSIONS: The FME developed in this study enables the rapid and efficient extraction of nucleic acid from respiratory samples, laying a crucial foundation for the implementation of expedited molecular diagnosis.
Sujet(s)
ARN viral , Réaction de polymérisation en chaine en temps réel , Humains , ARN viral/isolement et purification , ARN viral/génétique , ARN viral/analyse , Réaction de polymérisation en chaine en temps réel/méthodes , Virus de la grippe A/isolement et purification , Virus de la grippe A/génétique , Infections de l'appareil respiratoire/virologie , Infections de l'appareil respiratoire/diagnostic , Manipulation d'échantillons/méthodes , Facteurs temps , Virus/isolement et purification , Virus/génétique , Grippe humaine/diagnostic , Grippe humaine/virologie , Techniques de diagnostic moléculaire/méthodesRÉSUMÉ
Influenza (flu) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar clinical symptoms, complicating the diagnosis and clinical management of these critical respiratory infections. Thus, there is an urgent need for rapid on-site detection technologies that can simultaneously detect SARS-CoV-2 and influenza A viruses. Here, we have developed the first platform that combines in situ sampling with immune swabs and multichannel surface-enhanced Raman spectroscopy (SERS) for simultaneous screening of these two respiratory viruses in a single assay. A seed-mediated growth method was used to assemble a number of silver spheres on the surface of Fe3O4@SiO2 spheres, which not only creates extensive Raman hotspots but also provides numerous sites for Raman signaling molecules, enhancing the sensing sensitivity. Integrating two specific Raman signaling molecules into the nanospheres allows for the parallel detection of both viruses, improving the efficiency of SERS signal read-out. Rapid quantitative screening of both SARS-CoV-2 and H1N1 is achievable within 15 min, with detection limits of 7.76, and 8.13 pg·mL-1 for their respective target proteins. The platform demonstrated excellent performance in testing and analyzing 98 clinical samples (SARS-CoV-2:50; influenza A:48), achieving sensitivities of 88.00, and 95.83% for SARS-CoV-2 and influenza A, respectively. Pearson's correlation analysis revealed a significant correlation with the clinical CT values (P < 0.0001), underscoring the great potential of this platform for the early, rapid, and simultaneous diagnostic discrimination of multiple pathogens.
Sujet(s)
COVID-19 , Virus de la grippe A , SARS-CoV-2 , Argent , Analyse spectrale Raman , Analyse spectrale Raman/méthodes , SARS-CoV-2/isolement et purification , Humains , COVID-19/diagnostic , COVID-19/virologie , Argent/composition chimique , Virus de la grippe A/isolement et purification , Silice/composition chimique , Grippe humaine/diagnostic , Grippe humaine/virologie , Nanoparticules métalliques/composition chimiqueRÉSUMÉ
INTRODUCTION: Query (Q) fever is a zoonosis caused by the bacterium Coxiella burnetii typically presenting as an influenza-like illness (ILI) with or without hepatitis. The infection may be missed by clinicians in settings of low endemicity, as the presentation is clinically not specific, and there are many more common differential diagnoses for ILI including SARS-CoV-2 infection. METHODS: Residual serum samples were retrospectively tested for Phase 1 and 2 Q fever-specific IgM, IgG, IgA antibodies by indirect immunofluorescence and C. burnetii DNA by polymerase chain reaction. They had not been previously tested for Q fever, originating from undiagnosed patients with probable ILI, aged 10-70 years and living in regional New South Wales, Australia. The results were compared with contemperaneous data on acute Q fever diagnostic tests which had been performed based on clinicians requests from a geographically similar population. RESULTS: Only one (0.2%) instance of missed acute Q fever was identified after testing samples from 542 eligible patients who had probable ILI between 2016-2023. Laboratory data showed that during the same period, 731 samples were tested for acute Q fever for clinician-initiated requests and of those 70 (9.6%) were positive. Probability of being diagnosed with Q fever after a clinician initiated request was similar regardless of the patients sex, age and the calendar year of sampling. CONCLUSION: In this sample, Q fever was most likely to be diagnosed via clinician requested testing rather than by testing of undiagnosed patients with an influenza like illness.
Sujet(s)
Coxiella burnetii , Grippe humaine , Fièvre Q , Humains , Fièvre Q/diagnostic , Fièvre Q/épidémiologie , Nouvelle-Galles du Sud/épidémiologie , Adulte d'âge moyen , Adulte , Adolescent , Mâle , Sujet âgé , Femelle , Jeune adulte , Enfant , Grippe humaine/épidémiologie , Grippe humaine/diagnostic , Grippe humaine/virologie , Études rétrospectives , Coxiella burnetii/génétique , Coxiella burnetii/isolement et purification , Coxiella burnetii/immunologie , Anticorps antibactériens/sang , Diagnostic différentiel , COVID-19/diagnostic , COVID-19/épidémiologie , Immunoglobuline M/sangRÉSUMÉ
Plastic bronchitis is a relatively uncommon illness that has been reported in all age groups. This case report describes a specific manifestation of plastic bronchitis in two pediatric brothers influenced by both smoke inhalation and influenza A virus infection. The therapeutic approach mainly involved symptomatic supportive care, antiviral therapy, repeated bronchoscopic alveolar lavage, and bronchial cast removal. Eventually, both patients went into remission. Bronchoscopy proved to be helpful in diagnosing and treating these cases.
Sujet(s)
Bronchite , Bronchoscopie , Grippe humaine , Humains , Grippe humaine/complications , Grippe humaine/diagnostic , Bronchite/diagnostic , Bronchite/étiologie , Mâle , Lésion par inhalation de fumée/thérapie , Lésion par inhalation de fumée/complications , Antiviraux/usage thérapeutique , Enfant , Virus de la grippe A/isolement et purification , Lavage bronchoalvéolaireRÉSUMÉ
The similar transmission patterns and early symptoms of respiratory viral infections, particularly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza (H1N1), and respiratory syncytial virus (RSV), pose substantial challenges in the diagnosis, therapeutic management, and handling of these infectious diseases. Multiplexed point-of-care testing for detection is urgently needed for prompt and efficient disease management. Here, we introduce an electrochemical paper-based analytical device (ePAD) platform for multiplexed and label-free detection of SARS-CoV-2, H1N1, and RSV infection using immobilized pyrrolidinyl peptide nucleic acid probes. Hybridization between the probes and viral nucleic acid targets causes changes in the electrochemical response. The resulting sensor offers high sensitivity and low detection limits of 0.12, 0.35, and 0.36 pM for SARS-CoV-2 (N gene), H1N1, and RSV, respectively, without showing any cross-reactivities. The amplification-free detection of extracted RNA from 42 nasopharyngeal swab samples was successfully demonstrated and validated against reverse-transcription polymerase chain reaction (range of cycle threshold values: 17.43-25.89). The proposed platform showed excellent clinical sensitivity (100 %) and specificity (≥97 %) to achieve excellent agreement (κ ≥ 0.914) with the standard assay, thereby demonstrating its applicability for the screening and diagnosis of these respiratory diseases.
Sujet(s)
Techniques de biocapteur , Techniques électrochimiques , Sous-type H1N1 du virus de la grippe A , Papier , Acides nucléiques peptidiques , SARS-CoV-2 , Techniques de biocapteur/méthodes , Sous-type H1N1 du virus de la grippe A/isolement et purification , Sous-type H1N1 du virus de la grippe A/génétique , Techniques électrochimiques/méthodes , Humains , SARS-CoV-2/isolement et purification , SARS-CoV-2/génétique , Acides nucléiques peptidiques/composition chimique , COVID-19/diagnostic , COVID-19/virologie , ARN viral/analyse , ARN viral/génétique , Infections à virus respiratoire syncytial/diagnostic , Infections à virus respiratoire syncytial/virologie , Limite de détection , Grippe humaine/diagnostic , Grippe humaine/virologie , Virus respiratoires syncytiaux/isolement et purification , Virus respiratoires syncytiaux/génétique , Virus respiratoire syncytial humain/isolement et purification , Virus respiratoire syncytial humain/génétiqueRÉSUMÉ
Sensitive, convenient and rapid detection and subtyping of influenza viruses are crucial for timely treatment and management of infected people. Compared with antigen detection, nucleic acid detection has higher specificity and can shorten the detection window. Hence, in this work, we improved the lateral flow assay (LFA, one of the most promising user-friendly and on-site methods) to achieve detection and subtyping of H1N1, H3N2 and H9N2 influenza virus nucleic acids. Firstly, the antigen-antibody recognition mode was transformed into a nucleic acid hybridization reaction. Secondly, Fe3O4-Au heterodimer nanoparticles were prepared to replace frequently used Au nanoparticles to obtain better coloration. Thirdly, four lines were arranged on the LFA strip, which were three test (T) lines and one control (C) line. Three T lines were respectively sprayed by the DNA sequences complementary to one end of H1N1, H3N2 and H9N2 influenza virus nucleic acids, while Fe3O4-Au nanoparticles were respectively coupled with the DNA sequences complementary to the other end of H1N1, H3N2 and H9N2 nucleic acids to construct three kinds of probes. The C line was sprayed by the complementary sequences to the DNAs on all three kinds of probes. In the detection, by hybridization reaction, the probes were combined with their target nucleic acids which were captured by the corresponding T lines to form color bands. Finally, according to the position of the color bands and their grey intensity, simultaneous qualitative and semi-quantitative detection of the three influenza virus nucleic acids was realized. The detection results showed that this multi-channel LFA had good specificity, and there was no significant cross reactivity among the three subtypes of influenza viruses. The simultaneous detection achieved comparable detection limits with individual detections. Therefore, this multi-channel LFA had good application potential for sensitive and rapid detection and subtyping of influenza viruses.
Sujet(s)
Or , Or/composition chimique , Humains , Sous-type H3N2 du virus de la grippe A/composition chimique , Sous-type H3N2 du virus de la grippe A/isolement et purification , Nanoparticules métalliques/composition chimique , Sous-type H1N1 du virus de la grippe A/isolement et purification , Sous-type H1N1 du virus de la grippe A/composition chimique , Sous-type H1N1 du virus de la grippe A/immunologie , Sous-type H9N2 du virus de la grippe A/composition chimique , Sous-type H9N2 du virus de la grippe A/isolement et purification , Hybridation d'acides nucléiques/méthodes , ADN viral/analyse , Grippe humaine/diagnostic , Nanoparticules de magnétite/composition chimique , Limite de détectionRÉSUMÉ
Introduction: It is not always possible to differentiate between influenza and COVID-19 based on symptoms alone. This is a topic of significant importance as it aims to determine whether there are specific hematological parameters that can be used to distinguish between influenza and COVID-19 in children. Methodology: Two hundred thirty-one children between the ages of 1 month and 18 years who presented to the children's outpatient clinic between June 2021 and June 2022 with similar symptoms and were tested with an influenza test and a COVID-19 PCR test were included in the study. Of the patients included in the study, 130 tested positive for COVID-19 and 101 positive for influenza. The patients were evaluated for hematological parameters. Results: Age, eosinophils and monocyte factors were shown to be statistically significantly effective in COVID-19. The risk of COVID-19 increased 1,484-fold with age, 10,708-fold with increasing eosinophil count, and 1,591-fold with increasing monocyte count. The performance of the monocyte count and eosinophil count was assessed by receiver operating characteristic curve (ROC) analysis. According to the performed ROC analysis, the area under the curve (AUC) value was observed to be 0.990 for monocytes. According to the cutoff point >1.50, the sensitivity value was determined as 98.4% and the specificity value as 97.0%. AUC significance for eosinophils was found to be 0.989. According to the cutoff point >0.02, the sensitivity value was determined as 99.2% and the specificity value as 93.1%. Conclusion: In the diagnosis of COVID-19, the eosinophil count and monocyte count are easily accessible, inexpensive, and important parameters in terms of differential diagnosis and can help in the differentiation of COVID-19 from influenza during seasonal outbreaks of the latter. Developing parameters for clinicians to use in diagnosing COVID-19 and influenza can facilitate their work in practice.
Sujet(s)
COVID-19 , Grippe humaine , Humains , COVID-19/diagnostic , Enfant , Grippe humaine/diagnostic , Enfant d'âge préscolaire , Nourrisson , Adolescent , Mâle , Femelle , Diagnostic différentiel , SARS-CoV-2/isolement et purification , Courbe ROC , Granulocytes éosinophiles , Numération des leucocytes , MonocytesRÉSUMÉ
An increased risk for human infection with avian influenza A(H5N1) viruses is of concern. We developed an internally controlled, dual-target reverse transcription PCR for influenza A(H5) subtyping. This test could be used to detect influenza A(H5) in clinical samples.
Sujet(s)
Grippe chez les oiseaux , Grippe humaine , RT-PCR , Humains , Animaux , Grippe chez les oiseaux/virologie , Grippe chez les oiseaux/diagnostic , Grippe humaine/virologie , Grippe humaine/diagnostic , RT-PCR/méthodes , Sous-type H5N1 du virus de la grippe A/génétique , Sous-type H5N1 du virus de la grippe A/classification , Sous-type H5N1 du virus de la grippe A/isolement et purification , Oiseaux/virologie , Réaction de polymérisation en chaine multiplex/méthodes , Glycoprotéine hémagglutinine du virus influenza/génétique , Virus de la grippe A/génétique , Virus de la grippe A/classification , Virus de la grippe A/isolement et purificationRÉSUMÉ
OBJECTIVES: Influenza and Mycoplasma pneumoniae infections often present concurrent and overlapping symptoms in clinical manifestations, making it crucial to accurately differentiate between the two in clinical practice. Therefore, this study aims to explore the potential of using peripheral blood routine parameters to effectively distinguish between influenza and Mycoplasma pneumoniae infections. METHODS: This study selected 209 influenza patients (IV group) and 214 Mycoplasma pneumoniae patients (MP group) from September 2023 to January 2024 at Nansha Division, the First Affiliated Hospital of Sun Yat-sen University. We conducted a routine blood-related index test on all research subjects to develop a diagnostic model. For normally distributed parameters, we used the T-test, and for non-normally distributed parameters, we used the Wilcoxon test. RESULTS: Based on an area under the curve (AUC) threshold of ≥ 0.7, we selected indices such as Lym# (lymphocyte count), Eos# (eosinophil percentage), Mon% (monocyte percentage), PLT (platelet count), HFC# (high fluorescent cell count), and PLR (platelet to lymphocyte ratio) to construct the model. Based on these indicators, we constructed a diagnostic algorithm named IV@MP using the random forest method. CONCLUSIONS: The diagnostic algorithm demonstrated excellent diagnostic performance and was validated in a new population, with an AUC of 0.845. In addition, we developed a web tool to facilitate the diagnosis of influenza and Mycoplasma pneumoniae infections. The results of this study provide an effective tool for clinical practice, enabling physicians to accurately diagnose and differentiate between influenza and Mycoplasma pneumoniae infection, thereby offering patients more precise treatment plans.
Sujet(s)
Grippe humaine , Mycoplasma pneumoniae , Pneumopathie à mycoplasmes , Humains , Pneumopathie à mycoplasmes/diagnostic , Pneumopathie à mycoplasmes/sang , Grippe humaine/diagnostic , Grippe humaine/sang , Mâle , Femelle , Mycoplasma pneumoniae/isolement et purification , Adulte , Adulte d'âge moyen , Diagnostic différentiel , Jeune adulte , Adolescent , Algorithmes , Enfant , Sujet âgéRÉSUMÉ
Seasonal increase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus A/B (Flu A/B), and respiratory syncytial virus (RSV) require rapid diagnostic test methods for the management of respiratory tract infections. In this study, we compared the diagnostic accuracy of Savanna RVP4 (RVP4, QuidelOrtho) with Xpert Xpress Plus SARS-CoV-2/Flu/RSV (Xpert, Cepheid). Nasopharyngeal swabs from patients treated at a tertiary care hospital (Germany) were tested for SARS-CoV-2, Flu A/B, and RSV by RVP4 to assess diagnostic accuracy (reference standard: Xpert). The intra and inter assay precision of Ct-values was assessed by repeated test in triplicates (on day 1) and duplicates (days 2-3). All patients with a physician's order for a multiplex test for SARS-CoV-2, Flu, and RSV test were included. Duplicate swabs from the same patient, samples with a total volume ≤1 mL, or inappropriate shipment/storage were excluded. In total, 229 swabs were included between September 2023 and February 2024. The concordance between both tests was 96.5% (SARS-CoV-2), 98.7% (Flu A), and 99.6% (RSV). Flu B was not detected by both tests. The RVP4 test had a sensitivity of 85%-95% and a specificity of 100% for the detection of SARS-CoV-2, Flu A, and RSV. The intra and inter assay precision of Ct-values from RVP4 was 3% and 2% (SARS-CoV-2), 5% and 4% (Flu A), and 0% and 3% (RSV), respectively. The Savanna RVP4 has a favorable diagnostic accuracy for the detection of SARS-CoV-2, Flu A, and RSV. IMPORTANCE: We assessed the diagnostic accuracy of a new point-of-care test for the rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus A/B (Flu A/B), and respiratory syncytial virus (RSV). The new test has a concordance with the reference standard of 96.5% (SARS-CoV-2), 98.7% (Flu A), and 99.1% (RSV). The sensitivity of 85%-95% and specificity of 100% for the detection of SARS-CoV-2, Flu A, and RSV is comparable with similar nucleic acid amplification-based point of care tests but at lower costs.
Sujet(s)
COVID-19 , Virus de la grippe A , Grippe humaine , Infections à virus respiratoire syncytial , SARS-CoV-2 , Sensibilité et spécificité , Humains , COVID-19/diagnostic , SARS-CoV-2/isolement et purification , SARS-CoV-2/génétique , Virus de la grippe A/isolement et purification , Grippe humaine/diagnostic , Grippe humaine/virologie , Infections à virus respiratoire syncytial/diagnostic , Infections à virus respiratoire syncytial/virologie , Virus influenza B/isolement et purification , Partie nasale du pharynx/virologie , Femelle , Virus respiratoire syncytial humain/isolement et purification , Virus respiratoire syncytial humain/génétique , Adulte d'âge moyen , Mâle , Adulte , Sujet âgé , Infections de l'appareil respiratoire/diagnostic , Infections de l'appareil respiratoire/virologie , Allemagne , Virus respiratoires syncytiaux/isolement et purificationRÉSUMÉ
OBJECTIVES: This study evaluated relative vaccine effectiveness (rVE) of MF59-adjuvanted trivalent inactivated influenza vaccine (aTIV) vs high-dose trivalent inactivated influenza vaccine (HD-TIV) for prevention of test-confirmed influenza emergency department visits and/or inpatient admissions ("ED/IP") and for IP admissions alone pooled across the 2017-2020 influenza seasons. Exploratory individual season analyses were also performed. METHODS: This retrospective test-negative design study included United States (US) adults age ≥65 years vaccinated with aTIV or HD-TIV who presented to an ED or IP setting with acute respiratory or febrile illness during the 2017-2020 influenza seasons. Test-positive cases and test-negative controls were grouped by vaccine received. The rVE of aTIV vs HD-TIV was evaluated using a combination of inverse probability of treatment weighting and logistic regression to adjust for potential confounders. RESULTS: Pooled analyses over the three seasons found no significant differences in the rVE of aTIV vs HD-TIV for prevention of test-confirmed influenza ED/IP (-2.5% [-19.6, 12.2]) visits and admissions or IP admissions alone (-1.6% [-22.5, 15.7]). The exploratory individual season analyses also showed no significant differences. CONCLUSIONS: Evidence from the 2017-2020 influenza seasons indicates aTIV and HD-TIV are comparable for prevention of test-confirmed influenza ED/IP visits in US adults age ≥65 years.
Sujet(s)
Adjuvants immunologiques , Hospitalisation , Vaccins antigrippaux , Grippe humaine , Polysorbates , Saisons , Squalène , , Humains , Vaccins antigrippaux/immunologie , Vaccins antigrippaux/administration et posologie , Grippe humaine/prévention et contrôle , Grippe humaine/diagnostic , Grippe humaine/épidémiologie , Sujet âgé , Mâle , Femelle , Hospitalisation/statistiques et données numériques , Études rétrospectives , Polysorbates/administration et posologie , Squalène/administration et posologie , Adjuvants immunologiques/administration et posologie , États-Unis/épidémiologie , Sujet âgé de 80 ans ou plus , Vaccins inactivés/administration et posologie , Vaccins inactivés/immunologie , VaccinationRÉSUMÉ
Combination COVID-19/influenza rapid tests provide a way to quickly and accurately differentiate between the two infections. The goal of this economic evaluation was to assess the cost and health benefits of a combination COVID-19/influenza Rapid Diagnostic Test (RDT) vs. current standard-of-care in the Brazilian private healthcare setting. A dual decision tree model was developed to estimate the impact of rapid differentiation of COVID-19 and influenza in a hypothetical cohort of 1,000 adults with influenza-like illness in an ambulatory healthcare setting. The model compared the use of a combination COVID-19/influenza RDT to Brazil standard diagnostic practice of a COVID-19 RDT and presumptive influenza diagnosis. Different levels of influenza prevalence were modeled with co-infection estimated as a function of the COVID-19 prevalence. Outcomes included accuracy of diagnosis, antiviral prescriptions and healthcare resource use (hospital bed days and ICU occupancy). Depending on influenza prevalence, considering 1,000 patients with influenza-like illness, a combination RDT compared to standard practice was estimated to result in between 88 and 149 fewer missed diagnoses of influenza (including co-infection), 161 to 185 fewer cases of over-diagnosis of influenza; a 24 to 34% reduction in hospital bed days and a 16 to 26% reduction in ICU days. In the base case scenario (20% influenza, 5% COVID-19), the combination RDT was estimated to result in cohort cost savings of $99. Based upon a de novo economic model, this analysis indicates that use of a combination RDT could positively impact influenza antiviral prescriptions and lower healthcare resource use.
Sujet(s)
COVID-19 , Grippe humaine , Humains , COVID-19/diagnostic , Brésil/épidémiologie , Grippe humaine/diagnostic , Grippe humaine/économie , Analyse coût-bénéfice , Adulte , SARS-CoV-2 , Dépistage de la COVID-19/économie , Dépistage de la COVID-19/méthodes , Co-infection , Tests de diagnostic rapideRÉSUMÉ
Pathogenic microorganisms play a crucial role in the global disease burden due to their ability to cause various diseases and spread through multiple transmission routes. Immunity tests identify antigens related to these pathogens, thereby confirming past infections and monitoring the host's immune response. Traditional pathogen detection methods, including enzyme-linked immunosorbent assays (ELISAs) and chemiluminescent immunoassays (CLIAs), are often labor-intensive, slow, and reliant on sophisticated equipment and skilled personnel, which can be limiting in resource-poor settings. In contrast, the development of microfluidic technologies presents a promising alternative, offering automation, miniaturization, and cost efficiency. These advanced methods are poised to replace traditional assays by streamlining processes and enabling rapid, high-throughput immunity testing for pathogens. This review highlights the latest advancements in microfluidic systems designed for rapid and high-throughput immunity testing, incorporating immunosensors, single molecule arrays (Simoas), a lateral flow assay (LFA), and smartphone integration. It focuses on key pathogenic microorganisms such as SARS-CoV-2, influenza, and the ZIKA virus (ZIKV). Additionally, the review discusses the challenges, commercialization prospects, and future directions to advance microfluidic systems for infectious disease detection.
Sujet(s)
SARS-CoV-2 , Humains , SARS-CoV-2/immunologie , SARS-CoV-2/isolement et purification , Microfluidique/méthodes , Microfluidique/instrumentation , COVID-19/immunologie , COVID-19/diagnostic , COVID-19/virologie , Techniques d'analyse microfluidique/instrumentation , Techniques d'analyse microfluidique/méthodes , Dosage immunologique/méthodes , Virus Zika/immunologie , Laboratoires sur puces , Techniques de biocapteur/méthodes , Grippe humaine/diagnostic , Grippe humaine/immunologie , Infection par le virus Zika/diagnostic , Infection par le virus Zika/immunologieRÉSUMÉ
Acute respiratory tract infections, including influenza A (FluA), respiratory syncytial virus (RSV) infection, and COVID-19, can aggravate to levels requiring hospitalization, increasing morbidity and mortality. Identifying biomarkers for an accurate diagnosis and prognosis of these infections is a clinical need. We performed a cross-sectional study aimed to investigate the changes in circulating levels of arachidonic acid, interleukin 6 (IL-6), and C-reactive protein (CRP) in patients with FluA, RSV, or COVID-19, and to analyze the potential of these parameters as diagnosis or prognosis biomarkers. We analyzed serum samples from 172 FluA, 80 RSV, and 217 COVID-19 patients, and 104 healthy volunteers. Individuals with lung viral diseases showed reduced arachidonic acid concentrations compared to healthy people, with these differences being most pronounced in the order COVID-19 > RSV > FluA. Conversely, IL-6 and CRP levels were elevated across diseases, with IL-6 emerging as the most promising diagnostic biomarker, with areas under the curve (AUC) of the receiver operating characteristics plot higher than 0.85 and surpassing arachidonic acid and CRP. Moreover, IL-6 displayed notable efficacy in distinguishing between FluA patients who survived and those who did not (AUC = 0.80). These findings may provide useful tools for diagnosing and monitoring the severity of acute viral respiratory tract infections, ultimately improving patient outcomes.
Sujet(s)
Acide arachidonique , Protéine C-réactive , COVID-19 , Grippe humaine , Interleukine-6 , Infections à virus respiratoire syncytial , Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Acide arachidonique/sang , Marqueurs biologiques/sang , Protéine C-réactive/analyse , COVID-19/sang , COVID-19/diagnostic , Études transversales , Virus de la grippe A , Grippe humaine/sang , Grippe humaine/diagnostic , Grippe humaine/virologie , Interleukine-6/sang , Infections à virus respiratoire syncytial/sang , Infections à virus respiratoire syncytial/diagnostic , Courbe ROCRÉSUMÉ
Influenza(flu) in pregnancy is associated with higher rates of hospitalization, ICU admission, and death and with increased odds of congenital anomalies and stillbirth, but not preterm birth. Clinical manifestations of flu in pregnancy are the same as nonpregnant patients. Pregnant individuals with flu-like symptoms or flu exposure should be treated with antivirals. Diagnostic testing is not needed. Oseltamivir is the mainstay of treatment(and prophylaxis), and when given within 48 hours of symptom onset, it decreases morbidity and mortality. Influenza is associated with worse maternal, obstetric, and neonatal outcomes. These risks are mitigated by early oseltamivir treatment and maternal vaccination; hence the recommendation for universal vaccination in pregnancy.